Astellas Sets Up Indian Subsidiary To Market Branded Drugs
This article was originally published in PharmAsia News
Astellas Pharma has established Astellas Pharma India in Mumbai with a stake of about $3.1 million. The Indian subsidiary is intended to boost Astellas' presence in emerging markets, with a particular emphasis on immunology and urology products. Astellas India plans to release its first immunosuppressant, Prograf (tacrolimus), in the next fiscal year, followed by alpha-1 blocker Harnal for prostates and Vesicare (solifenacin) for bladder problems. The new company does not intend to sell generics of other drugs. (Click here for more - a subscription may be required
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.